Characterization of vasoactive intestinal peptide receptors in human liver.

Rodríguez-Henche N, Rodríguez-Pena MS, Guijarro LG, Prieto JC

Biochimica et biophysica acta1 Mar 1994Cited by 13 (Europe PMC)

PMID8148398DOI10.1016/0167-4889(94)90013-2PepBankPUB-08148398

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In human liver membranes, VIP bound two classes of sites, with Kd of 0.22 nM at the high-affinity site and 27.3 nM at the low-affinity site.
In plain wordsIn lab tests on human liver membranes, VIP bound to two kinds of receptor sites, one with much higher affinity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicable[125I]VIP binding affinity (Kd), human liver membranes
Study
humann: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
Kd high-affinity
0.22 nM
human liver membranes
Kd low-affinity
27.3 nM
human liver membranes
Source sentences
Summary
The stoichiometric data indicated the presence of two classes of binding sites in both human and rat liver membranes with Kd values of 0.22 (human) and 0.20 (rat) nM for the high-affinity site, and 27.3 (human) and 3.6 (rat) nM for the low-affinity site.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839801
02LabEx vivo tissueActivity measurement
In rat liver membranes, VIP bound two classes of sites, with Kd of 0.20 nM at the high-affinity site and 3.6 nM at the low-affinity site.
In plain wordsIn lab tests on rat liver membranes, VIP bound to two kinds of receptor sites, one with much higher affinity.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicable[125I]VIP binding affinity (Kd), rat liver membranes
Study
ratn: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
Kd high-affinity
0.2 nM
rat liver membranes
Kd low-affinity
3.6 nM
rat liver membranes
Source sentences
Summary
The stoichiometric data indicated the presence of two classes of binding sites in both human and rat liver membranes with Kd values of 0.22 (human) and 0.20 (rat) nM for the high-affinity site, and 27.3 (human) and 3.6 (rat) nM for the low-affinity site.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839802
03LabEx vivo tissueActivity measurement
In human liver membranes, tracer VIP binding was displaced with a potency order of VIP = PACAP-27 > helodermin > secretin.
In plain wordsIn lab tests on human liver membranes, VIP and PACAP-27 were equally potent at displacing VIP binding, more than helodermin and secretin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePotency order of peptides displacing VIP binding, human liver
Study
humann: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Tracer binding was displaced by structurally related peptides with an order of potency: VIP = PACAP-27 > helodermin > secretin in human liver, and VIP = PACAP-27 = helodermin > secretin in rat liver.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839803
04LabEx vivo tissueActivity measurement
In rat liver membranes, tracer VIP binding was displaced with a potency order of VIP = PACAP-27 = helodermin > secretin.
In plain wordsIn lab tests on rat liver membranes, VIP, PACAP-27 and helodermin were equally potent at displacing VIP binding, more than secretin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePotency order of peptides displacing VIP binding, rat liver
Study
ratn: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Tracer binding was displaced by structurally related peptides with an order of potency: VIP = PACAP-27 > helodermin > secretin in human liver, and VIP = PACAP-27 = helodermin > secretin in rat liver.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839804
05LabEx vivo tissueMechanism
In liver membranes, GTP inhibited [125I]VIP binding in a dose-dependent manner, which suggests that a G protein is involved.
In plain wordsIn lab tests on liver membranes, GTP reduced VIP binding, which suggests a G protein takes part in the signal.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEffect of GTP on VIP binding
Study
n: not reported in source
liver membranes
Comparator
No GTP
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
GTP inhibited [125I]VIP binding in a dose-dependent manner suggesting the involvement of a G protein in the signal transduction pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839805
06LabEx vivo tissueActivity measurement
In human liver membranes, VIP stimulated adenylyl cyclase activity in a dose-dependent manner, with an ED50 of 1.2 nM.
In plain wordsIn lab tests on human liver membranes, VIP switched on the enzyme adenylyl cyclase, so the receptors work.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP-stimulated adenylyl cyclase activity (ED50), human liver
Study
humann: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
ED50
1.2 nM
human liver membranes
Source sentences
Summary
VIP receptors were functional, since VIP stimulated adenylyl cyclase activity in a dose dependent manner with similar efficacy but different potency in human (ED50 = 1.2 nM) and rat (ED50 = 5.8 nM) liver membranes.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839807
07LabEx vivo tissueActivity measurement
In rat liver membranes, VIP stimulated adenylyl cyclase activity in a dose-dependent manner, with an ED50 of 5.8 nM.
In plain wordsIn lab tests on rat liver membranes, VIP switched on the enzyme adenylyl cyclase, with lower potency than in human membranes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP-stimulated adenylyl cyclase activity (ED50), rat liver
Study
ratn: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
ED50
5.8 nM
rat liver membranes
Source sentences
Summary
VIP receptors were functional, since VIP stimulated adenylyl cyclase activity in a dose dependent manner with similar efficacy but different potency in human (ED50 = 1.2 nM) and rat (ED50 = 5.8 nM) liver membranes.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
Report a problemFND-0814839808

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther
Cross-linking gave an apparent molecular mass of the VIP-receptor complex of 67,500 in human liver and 50,500 in rat liver preparations.
In plain wordsIn lab tests, the VIP-receptor complex had a different size in human liver than in rat liver.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableMolecular mass of the VIP-receptor complex (cross-linking)
Study
humann: not reported in source
liver membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Cross-linking experiments revealed an apparent molecular mass for the VIP-receptor complex that was 67,500 +/- 2700 and 50,500 +/- 900 in human and rat preparations, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0814839806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.